Calley Means at the Financial Times' US Pharma and Biotech Summit (Wiktoria Warpas for the Financial Times)
May 15, 2025 06:36 PM EDTUpdated 07:04 PM
Pharma
Manufacturing

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

Max Gelman

Senior Editor

NEW YORK — Cal­ley Means, a spe­cial White House em­ploy­ee and top ad­vi­sor to HHS Sec­re­tary Robert F. Kennedy Jr., ef­fec­tive­ly dared Roche to pull its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

New CBER chief Prasad is ready­ing 'mas­sive frame­work' around vac­cines, Makary says

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

Ex­clu­sive: Drug com­pounder Em­pow­er was built on risky short­cuts, ex-em­ploy­ees and in­spec­tions al­lege

Eli Lil­ly turns to South Ko­re­an RNA edit­ing biotech for hear­ing loss in deal worth $1.3B

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

A service from the Financial Times